BioEngine on the ranking list of Chinaventure vigorous 100

On February 2, 2023, the "ranking list of China venture vigorous 100" was officially released, and BioEngine was ranked on the list for our industry-leading innovation capability and vigorous development potential.

It is understood that Chinaventure has released the “vigorous 100” ranking list for three years, focusing on technology innovation tracks including cloud computing, big data, the internet of things, artificial intelligence, semiconductor chips, biomedicine, medical equipment, intelligent medical care, enterprise services. The list is based on the activity of the growth enterprises in the capital market in the above-mentioned fields, and the enterprises with high financing activity and strong growth are selected. The list selects the 100 most innovative and growing innovative technology enterprises from the three dimensions of external attention, industrial synergy, and industrial influence, through the process of registration, questionnaire research, industry expert visits, and data analysis.

Founded in 2014, BioEngine is dedicated to providing international quality and cost-effective serum-free medium products and professional technical services for biopharmaceutical companies such as antibody, vaccine, and cell/gene therapy treatment. We are committed to being the world's most reliable animal cell culture partner. And we are the project lead and co-author of the first 2 serum-free culture media association standards in China.

In 2022, BioEngine completed a 200 million RMB B++ round of financing and continued to invest in the innovation and research of product technology and the upgrade and optimization of production quality management. In the same year, the culture media production base of BioEngine successfully passed ISO13485:2016 and MDSAP quality management system certification, laying a solid foundation for the "Intelligent Manufacturing in China" culture media to serve customers in the global biopharmaceutical industry. The two association standards for serum-free culture media jointly developed by BioEngine have filled the gaps of domestic standards and continue to empower the vigorous development of the biopharmaceutical industry.